Clinical Trials

16 enrolled

Advance Solid Tumors

NCT06508034 2026-01-21

Probiotics for the Prevention of Immunotherapy Induced Colitis in Patients Receiving Immunotherapy

12 enrolled

Malignant Solid Neoplasm

NCT05844306 2025-11-19

RefleXion PET/CT Imaging Performance in Patients With Various Malignancies

20 enrolled

Hematopoietic and Lymphoid System Neoplasm

NCT05938296 2025-11-19

oHSV2-PD-L1/CD3-BsAb Administered Via Intratumoral Injection

29 enrolled

Solid Tumor

NCT06581211 2025-11-06

Aromatherapy Oil Associated for Managing Anxiety and Pain During Bone Marrow Biopsy Procedures

45 enrolled

Hematopoietic and Lymphatic System Neoplasm

NCT04381806 2025-10-29

Phase I Study in Advanced Malignancies With 5-ALA

130 enrolled

EndocrineGynecologicLymphoidOther solid neoplasmThoracic

Solid Tumor

NCT05337735 2025-10-09

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

Phase 2 Suspended

140 enrolled

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Hodgkin Disease, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05055518 2025-06-27

APL-102 Capsule in Patients With Advanced Solid Tumors

30 enrolled

Advanced Solid Tumor

NCT05571969 2025-05-07

Study to Determine the Maximum Tolerated Dose (MTD) of PARPi 2X-121 Monotherapy and the MTD of Dovitinib in Combination With 2X-121 in Patients With Advanced Solid Tumors

40 enrolled

Advanced Solid Tumors

NCT04485416 2025-04-10

CCPO011

10 enrolled

Solid Tumor, Childhood

NCT05416749 2024-11-20

A Clinical Study of 8MW2311 in Subjects With Locally Advanced or Metastatic Solid Tumors

Phase 1/2 Suspended

216 enrolled

Solid Tumors

NCT05076591 2024-10-30

IMM2902, a HER2/SIRPα Bispecific MAb-Trap Antibody-receptor Fusion Protein, in Patients with HER2-expressing Advanced Solid Tumors

BreastGastrointestinalOther solid neoplasm

135 enrolled

Advanced Solid Tumor

NCT03859752 2023-09-22

TR1801-ADC in Patients With Tumors That Express c-Met

15 enrolled

Other solid neoplasmThoracic

Unspecified Adult Solid Tumor, Protocol Specific

NCT01627795 2018-04-18

Safety and Efficacy of Oshadi D and Oshadi R for Malignant Mesothelioma Treatment

Phase 1/2 Suspended

17 enrolled

Mesothelioma, Malignant, Mesothelioma, Neoplasms

NCT00695032 2014-11-05

Kidney Damage in Patients Receiving Cisplatin and Ifosfamide for Solid Tumors

80 enrolled

Chemotherapeutic Agent Toxicity

NCT01762410 2014-09-29

Clinical Study of Oral PI3K/mTOR Inhibitor in Patients With Advanced Refractory Solid Tumors

60 enrolled

Advanced Refractory Solid Tumors

NCT01779336 2014-09-29

Clinical Study of Oral IGF-1R Inhibitor in Subjects With Advanced Refractory Solid Tumors

70 enrolled

Advanced Refractory Solid Tumors

NCT01604863 2012-11-01

A Study of HGS1036 in Combination With Chemotherapy in Subjects With Advanced Solid Malignancies

GenitourinaryOther solid neoplasmThoracic

54 enrolled

Lung Neoplasms, Mesothelioma, Neoplasms, Prostatic Neoplasms, Small Cell Lung Carcinoma

NCT00003980 2012-07-11

BIBX 1382 in Treating Patients With Solid Tumors

80 enrolled

Unspecified Adult Solid Tumor, Protocol Specific

NCT01226056 2010-10-21

Sorafenib in Combination With RAD001 in Advanced Solid Tumors Selected on Molecular Targets

Phase 1/2 Suspended

45 enrolled

Advanced Solid Tumors

NCT00591682 2008-03-26

MSX-122 Administered Orally in Patients With Refractory Metastatic or Locally Advanced Solid Tumors

27 enrolled